ArticleBMC urology2025
Plasma presepsin as a predictor of mortality in patients with UTI-related severe infection: a single-center retrospective study.
Article in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThis study aimed to evaluate whether plasma presepsin levels are a more reliable predictor of mortality than traditional infection biomarkers in patients with urinary tract infection (UTI)-related severe infection.
methodsThis single-center retrospective study evaluated 69 patients with UTI-related severe infection admitted to the emergency department between May 2022 and August 2023. Data on vital signs, plasma presepsin levels, procalcitonin (PCT) levels, C-reactive protein (CRP) levels, white blood cell (WBC) count, and other laboratory values at admission were collected. The values of presepsin, PCT, CRP, and WBC count for predicting 28-day mortality were analyzed. Survivors and non-survivors were propensity score-matched in a 2:1 ratio based on age, sex, and estimated glomerular filtration rate.
resultsIn the overall cohort, presepsin showed the highest area under the receiver operating characteristic curve (AUROC) of 0.716 for predicting 28-day mortality, surpassing that of PCT (0.641), CRP (0.488), and WBC count (0.433). Presepsin levels were independently associated with increased 28-day mortality risk (hazard ratio, 1.026; p = 0.008). In the matched cohort, presepsin levels showed the highest AUROC (0.660), followed by PCT (0.584), CRP (0.496), and WBC count (0.436).
conclusionsPresepsin levels were independently associated with increased 28-day mortality risk; this may be a valuable biomarker for identifying high-risk patients with UTI-related severe infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.